Moderna's mRNA-Based Influenza Shot Receives FDA Approval
The U.S. Food and Drug Administration has granted approval to Moderna's influenza vaccine, marking the first licensed flu shot built on messenger RNA technology. This milestone expands the use of mRNA platforms beyond COVID-19 vaccines. The decision could pave the way for more rapid updates to seasonal flu vaccines in future years.
Related stories
FDA Expands Vaccine Approvals for RSV, Flu, and Pneumococcal Disease · Infectious disease
GSK advances mRNA flu shot to late-stage trial after positive Phase 2 data · Infectious disease
FDA approves Ionis' RNA-based treatment for rare Alexander disease · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “FDA approves Moderna’s mRNA flu vaccine, the first to use the technology.” Browse more stories.